Ensuring strategy implementation through enhanced expertise and stability in management
With the vision announced in August 2014 of the division of the Group into two independent listed companies, Galenica entered a very significant but also sensitive phase. In order to prepare the division that is planned for the next two to four years in the best possible way and to ensure implementation of the strategy, the Board of Directors will propose to the shareholders at the Annual General Meeting on 7 May 2015 the election of two new Board members:
Furthermore, the Board of Directors wants to ensure that the Group's strategy is implemented consistently also through stability in management. Therefore the Board of Directors has agreed a new contract with Etienne Jornod until the 2020 Annual General Meeting.
Read more02
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
- Download PDF03
distributed by |